JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 5 July 2006. doi:10.1136/jcp.2006.040170
Journal of Clinical Pathology 2007;60:500-503
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2006.040170v1
60/5/500    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fons, G.
Right arrow Articles by ten Kate, F. J W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fons, G.
Right arrow Articles by ten Kate, F. J W

ORIGINAL ARTICLE

Validation of tissue microarray technology in endometrioid cancer of the endometrium

Guus Fons1, Siti M Hasibuan2, Jacobus van der Velden1, Fiebo J W ten Kate3

1 Academic Medical Centre, Department of Obstetrics and Gynaecology, Amsterdam, The Netherlands
2 Dr Pirngadi Hospital, Department of Anatomical Pathology, Medan, Indonesia
3 Academic Medical Centre, Department of Pathology, Amsterdam, The Netherlands

Correspondence to:
Dr G Fons
Academic Medical Centre Department of Obstetrics and Gynaecology Meibergdreef 9 1100 DD Amsterdam The Netherlands;g.fons{at}amc.uva.nl Aim: To validate tissue microarray (TMA) for endometrial cancer by comparing immunohistochemical staining results of triplicate core biopsies on TMA with the results of full-section analysis.

Methods: The study material consisted of slides and selected tissue blocks of 41 patients with endometrioid cancer of the endometrium. A TMA was constructed. Both the TMA and the slides were stained with the same antibodies against progesterone receptor (PR), oestrogen receptor, p53 and epithelial membrane antigen (EMA). Concordance between results was expressed as the {kappa} statistic.

Results: Concordance between the staining results of TMA and whole slides was good for PR ({kappa} = 0.69), oestrogen receptor ({kappa} = 0.78), p53 ({kappa} = 0.81) and EMA ({kappa} = 0.72). Concordance between the results on TMA and slides depends on the number of assessable cores per tumour. Three assessable cores per case result in outcomes that are at least 94% similar to those achieved using conventional tissue sections with a two-class scoring system. This is independent of focal or diffuse staining patterns.

Conclusion: TMA is a useful tool for further analysis of the molecular pathways in endometrial cancer. The effect of selection has to be taken into account when the prognostic value of protein expression on TMA is determined.


Abbreviations: EMA, epithelial membrane antigen; PR, progesterone receptor; TMA, tissue microarray







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.